Biofrontera Q3 Earnings Release: Demand Tested Following Lamp Sales Ban
BFRI Biofrontera Inc
$0.83 +2.50%
View chart & analysis → - 1The International Trade Commission banned the sale of Rodolet XL lamps and Ameluz after July 7.
- 2Biofrontera's projected Q3 revenue of approximately $8 million, per consensus, represents a 14.5% increase from $7 million a year ago.
- 3Biofrontera's projected Q3 net loss per share of $0.33, per consensus, is a 44% improvement from the $0.59 loss a year ago.
So what's the key point?
Biofrontera's product sales have been banned, but Q3 revenue is expected to increase to $8 million. Experts also expect the net loss to improve by 44% compared to last year.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.